(RTTNews) - Mirati Therapeutics, Inc. (MRTX) announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma. The company said the combination of sitravatinib with nivolumab showed promising clinical activity in checkpoint inhibitor-naïve, platinum-refractory patients. The sitravatinib and nivolumab combination has been well-tolerated in the study.
The ongoing, phase 2, open-label, multicenter trial in patients with advanced or metastatic urothelial carcinoma includes multiple patient cohorts that are defined based on prior therapy and platinum eligibility.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
